Skelaxin

Skelaxin is a brand name of metaxalone, approved by the FDA in the following formulation(s):

SKELAXIN (metaxalone - tablet; oral)

• 
  Manufacturer: KING PHARMS
  
  Approval date: August 30, 2002
  
  Strength(s): 800MG ^[RLD][AB]

Has a generic version of Skelaxin been approved?

A generic version of Skelaxin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Skelaxin and have been approved by the FDA:

metaxalone tablet; oral

• 
  Manufacturer: SANDOZ
  
  Approval date: March 31, 2010
  
  Strength(s): 800MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Skelaxin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for increasing the bioavailability of metaxalone
  Patent 6,407,128
  Issued: June 18, 2002
  Inventor(s): Michael; Scaife & Jaymin; Shah
  Assignee(s): Elan Pharmaceuticals, Inc.
  A method of increasing the bioavailability of metaxalone by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
  
  Patent expiration dates:
  
  
  • December 3, 2021
    
    ✓ 
    Patent use: ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
  
  



• 
  Methods of using metaxalone in the treatment of musculoskeletal conditions
  Patent 6,683,102
  Issued: January 27, 2004
  Inventor(s): Michael; Scaife & Jaymin; Shah
  Assignee(s): Elan Pharmaceuticals, Inc.
  A method of increasing the bioavailability of metaxalone by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
  
  Patent expiration dates:
  
  
  • December 3, 2021
    
    ✓ 
    Patent use: ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
  
  



• 
  Metaxalone products, method of manufacture, and method of use
  Patent 7,122,566
  Issued: October 17, 2006
  Inventor(s): Du; Jie & Roberts; Richard H.
  Assignee(s): Mutual Pharmaceutical Company, Inc.
  Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.
  
  Patent expiration dates:
  
  
  • February 6, 2026
    
    ✓ 
    Patent use: TREATMENT OF MUSCULOSKELETAL CONDITIONS
  
  



• 
  Methods of modifying the bioavailability of metaxalone
  Patent 7,714,006
  Issued: May 11, 2010
  Inventor(s): Scaife; Michael C. & Davis; Charles C.
  Assignee(s): King Pharmaceuticals Research & Development, Inc.
  A method of increasing the bioavailability, and decreasing the effect of age on the bioavailability, of metaxalone, by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability, and decreased effect of age on bioavailability, of the medication in the container, when taken with food.
  
  Patent expiration dates:
  
  
  • December 3, 2021
    
    ✓ 
    Patent use: USE OF METAXALONE FOR TREATMENT OF MUSCULSKELETAL CONDITIONS
  
  

See also...

• Skelaxin Consumer Information (Drugs.com)
• Skelaxin Consumer Information (Wolters Kluwer)
• Skelaxin Consumer Information (Cerner Multum)
• Skelaxin Advanced Consumer Information (Micromedex)
• Skelaxin AHFS DI Monographs (ASHP)
• Metaxalone Consumer Information (Wolters Kluwer)
• Metaxalone Consumer Information (Cerner Multum)
• Metaxalone Advanced Consumer Information (Micromedex)
• Metaxalone AHFS DI Monographs (ASHP)